Remarkable progress in cystic fibrosis —But why?
Publication date: Available online 28 January 2020Source: Journal of Biomedical InformaticsAuthor(s): Akhilesh Kumar Bajpai, Sravanthi Davuluri, Kriti Tiwary, Sithalechumi Narayanan, Sailaja Oguru, Kavyashree Basavaraju, Deena Dayalan, Kavitha Thirumurugan, Kshitish K. AcharyaAbstractIn absence of periodic systematic comparisons, biologists/bioinformaticians may be forced to make a subjective selection among the many protein-protein interaction (PPI) databases and tools. We conducted a comprehensive compilation and comparison of such resources. We compiled 375 PPI resources, short-listed 125 important ones (both lists are ...
ConclusionsIn addition to characterizing host gene expression and mucosal microbiome in cystic fibrosis patients, our study explored the potential role of host-microbe interactions in the etiology of colorectal cancer in cystic fibrosis. Our results provide biomarkers that may potentially serve as targets for stratifying risk of colorectal cancer in patients with cystic fibrosis.
Conditions: Cystic Fibrosis; Inflammation Interventions: Diagnostic Test: Genotyping; Diagnostic Test: Lung function; Diagnostic Test: Microbiology; Diagnostic Test: Blood sample; Diagnostic Test: Induced Sputum Sponsors: University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn); University Hospital, Frankfurt; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Recruiting
Contributors : Janina Treffon ; Diego Chaves-Moreno ; Silke Niemann ; Dietmar H Pieper ; Thomas Vogl ; Johannes Roth ; Barbara C KahlSeries Type : Expression profiling by high throughput sequencingOrganism : Staphylococcus aureusStaphylococcus aureus is one of the earliest pathogens that persists the airways of cystic fibrosis (CF) patients and contributes to increased inflammation and decreased lung function. In contrast to other staphylococci, S. aureus possesses two superoxide dismutases (SODs), SodA and SodM, with SodM being unique to S. aureus. Both SODs arm S. aureus for its fight against oxidative stress, a byproduc...
PMID: 31977412 [PubMed - in process]
Despite our differences, one thing we all have in common is death. One way or another, it's going to get each of us. Jeremie has been forced to meditate on that reality and it's had a profound effect on how he approaches life. In this keynote, Jeremie candidly and openly shares his story about growing up with Cystic Fibrosis and how he found laughter to be key as he shifted his perspective from seeing himself as someone who is dying from a fatal disease to someone who has been given the gift of a shortened life expectancy in order to make the most of it.
Trikafta, a combination of elexacaftor, ivacaftor, and tezacaftor, is a new drug for the treatment of the most common cystic fibrosis mutation.Serious adverse effects include elevated liver enzymes and an increased risk of cataracts.
CONCLUSION: Use of the CFTR modulator lumacaftor/ivacaftor was associated with significantly lower hepatic steatosis. No association between CFRD and hepatic steatosis was found in this cohort. PMID: 31966908 [PubMed]
A BEAMING Harriet Corr holds up her first box of life-saving cystic fibrosis pills, after a year of melting hearts in the Daily Express.
No abstract available
More News: Cystic Fibrosis